Circulating IGF-1 and IGFBP-2 may be biomarkers for risk stratification in patients with acute coronary syndrome: A prospective cohort study

• Published in: Nutrition, metabolism, and cardiovascular diseases metabolism, and cardiovascular diseases, 2023-09, Vol.33 (9), p.1740-1747
• Main Authors: Wang, Wei, Sun, Ying, Mo, De-Gang, Li, Tai, Yao, Heng-Chen
• Format: Article
• Language: English
• Subjects: ACS; Acute Coronary Syndrome - diagnosis; Biomarkers; Humans; IGF-1; IGFBP-2; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor I; Myocardial Infarction; Prospective Studies; Risk Assessment - methods; Risk stratification; TIMI risk Score
• ISSN: 0939-4753; 1590-3729
• DOI: 10.1016/j.numecd.2023.05.030

The involvement of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-2 (IGFBP-2) following acute coronary syndrome (ACS) is rarely studied in clinical practice. Therefore, we sought to evaluate the relationship between IGF-1 and IGFBP-2 concentrations at admission and risk stratification based on the Thrombolysis in Myocardial Infarction (TIMI) risk score in patients with ACS. In all, 304 patients diagnosed with ACS were included in this study. Plasma IGF-1 and IGFBP-2 were measured using commercially available ELISA kits. The TIMI risk score was calculated and the study population was stratified into high (n = 65), medium (n = 138), and low (n = 101) risk groups. Levels of IGF-1 and IGFBP-2 were analyzed for their predictive ability of risk stratification based on the TIMI risk scores. Correlation analysis showed that IGF-1 levels were negatively correlated with TIMI risk levels (r = −0.144, p = 0.012), while IGFBP-2 levels were significantly and positively correlated with TIMI risk levels (r = 0.309, p